C Keijzer1, B J Haijema2, T Meijerhof3, P Voorn2, A de Haan3, K Leenhouts4, M L van Roosmalen2, W van Eden1, F Broere1. 1. Department of Infectious Diseases and Immunology, Utrecht University, Yalelaan 1, NL-3584 CL Utrecht, The Netherlands. 2. Mucosis BV, L.J. Zielstraweg 1, NL-9713 GX Groningen, The Netherlands. 3. Department of Medical Microbiology, Molecular Virology Section, University of Groningen, University Medical Center Groningen, The Netherlands. 4. Mucosis BV, L.J. Zielstraweg 1, NL-9713 GX Groningen, The Netherlands. Electronic address: leenhouts@mucosis.com.
Abstract
BACKGROUND: Nasal vaccination is considered to be a promising alternative for parenteral vaccination against influenza virus as it is non-invasive and offers the opportunity to elicit strong antigen-specific responses both systemic and locally at the port of entry of the pathogen. Previous studies showed that non-living bacterium-like particles (BLPs) from the food-grade bacterium Lactococcus lactis are effective stimulators of local and systemic immune responses when administered intranasally. Moreover, in vitro, BLPs specifically interact with human Toll-like receptor 2 (TLR2), suggestive of a role for TLR2 dependent immune activation by BLPs. METHODS: In the present study, we examined the role of TLR2 in vivo in immune activation after nasal administration of BLP mixed with split influenza vaccine (BLP-SV) of influenza A virus (IAV) using TLR2 knockout mice. RESULTS: The systemic Th1 cell and subsequent B-cell responses induced after intranasal BLP-SV vaccination depended on the interaction of BLPs with TLR2. Notably, the BLP-SV-induced class switch to IgG2c depended on the interaction of BLP with TLR2. Local induced IAV-specific Th1 cell responses and the mucosal B-cell responses also depended on interaction of BLP with TLR2. Strongly reduced SIgA levels were observed in TLR2 knockout mice both in the nasal and vaginal lavages. In addition, detailed analysis of the T-cell response revealed that nasal BLP-SV vaccination promoted Th1/Th17 immune responses that coincided with increased IAV-specific IgG2c antibody production. DISCUSSION: Altogether these results indicate that nasal BLP-SV vaccination induces IAV-specific T-cell and B-cell responses, both systemically and at the site of virus entry in a TLR2-dependent manner.
BACKGROUND: Nasal vaccination is considered to be a promising alternative for parenteral vaccination against influenza virus as it is non-invasive and offers the opportunity to elicit strong antigen-specific responses both systemic and locally at the port of entry of the pathogen. Previous studies showed that non-living bacterium-like particles (BLPs) from the food-grade bacterium Lactococcus lactis are effective stimulators of local and systemic immune responses when administered intranasally. Moreover, in vitro, BLPs specifically interact with humanToll-like receptor 2 (TLR2), suggestive of a role for TLR2 dependent immune activation by BLPs. METHODS: In the present study, we examined the role of TLR2 in vivo in immune activation after nasal administration of BLP mixed with split influenza vaccine (BLP-SV) of influenza A virus (IAV) using TLR2 knockout mice. RESULTS: The systemic Th1 cell and subsequent B-cell responses induced after intranasal BLP-SV vaccination depended on the interaction of BLPs with TLR2. Notably, the BLP-SV-induced class switch to IgG2c depended on the interaction of BLP with TLR2. Local induced IAV-specific Th1 cell responses and the mucosal B-cell responses also depended on interaction of BLP with TLR2. Strongly reduced SIgA levels were observed in TLR2 knockout mice both in the nasal and vaginal lavages. In addition, detailed analysis of the T-cell response revealed that nasal BLP-SV vaccination promoted Th1/Th17 immune responses that coincided with increased IAV-specific IgG2c antibody production. DISCUSSION: Altogether these results indicate that nasal BLP-SV vaccination induces IAV-specific T-cell and B-cell responses, both systemically and at the site of virus entry in a TLR2-dependent manner.
Authors: Shyamal P Choudhari; Xiaotong Chen; Jae Hyun Kim; Maarten L Van Roosmalen; Jamie C Greenwood; Sangeeta B Joshi; William D Picking; Kees Leenhouts; C Russell Middaugh; Wendy L Picking Journal: J Pharm Sci Date: 2014-06-10 Impact factor: 3.534
Authors: Jack A Panapasa; Rebecca J Cox; Kristin G I Mohn; Lara A Aqrawi; Karl A Brokstad Journal: Hum Vaccin Immunother Date: 2015 Impact factor: 3.452
Authors: Shannon J Heine; Olga L Franco-Mahecha; Xiaotong Chen; Shyamal Choudhari; William C Blackwelder; Maarten L van Roosmalen; Kees Leenhouts; Wendy L Picking; Marcela F Pasetti Journal: Immunol Cell Biol Date: 2015-03-17 Impact factor: 5.126
Authors: Jasmine Tomar; Carin Biel; Cornelis A M de Haan; Peter J M Rottier; Nikolai Petrovsky; Henderik W Frijlink; Anke Huckriede; Wouter L J Hinrichs; Ben Peeters Journal: Eur J Pharm Biopharm Date: 2018-10-09 Impact factor: 5.571
Authors: C Facundo Temprana; Marcelo H Argüelles; Nicolás M Gutierrez; Patricia A Barril; Laura E Esteban; Dalila Silvestre; Marcelo G Mandile; Graciela Glikmann; Alejandro A Castello Journal: PLoS One Date: 2018-09-07 Impact factor: 3.240